Questions about this study?
The HopeStage team will email you.
TerminatedNCT00637494
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
This study evaluates the safety and effectiveness of mifepristone for people with depression.
Medication studyAges 22+United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of mifepristone for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 22 years. Other eligibility criteria apply.
- Listed locations
- Little Rock and 41 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateMarch 2008
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 292
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 22 Years
- Official registry ID
- NCT00637494
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Recruitment & locations
TerminatedLittle Rock · Anaheim · Downey
34 more locations
- Escondido
- Garden Grove
- Oakland
- Oceanside
- San Bernardino
- San Diego
- Aventura
- Gainesville
- Hollywood
- Kissimmee
- Miami
- Orlando
- Tampa
- Atlanta
- Hoffman Estates
- Flowood
- Creve Coeur
- St Louis
- Marlton
- Cedarhurst
- Glen Oaks
- Hope Mills
- Winston-Salem
- Dayton
- Oklahoma City
- Allentown
- Philadelphia
- Pittsburgh
- Charleston
- Austin
- Dallas
- DeSoto
- Houston
- Salt Lake City
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of mifepristone for people with depression.
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Does this study involve medication?
Yes. The study involves medication, including mifepristone and placebo.
Who can participate?
This study is for people with depression. Listed age limits: from 22 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolarity type I, and Major Depressive Disorder
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode